Photo taken on Nov. 9, 2021 shows the booth of Roche of Switzerland at the 4th China International Import Expo (CIIE) in east China's Shanghai. (Xinhua/Zhang Yuwei)
BEIJING, Oct. 11 (Xinhua) -- Swiss healthcare giant Roche announced on Monday that it would invest 250 million yuan in China in 2022, reported Chinanews.com.
Roche has invested 863 million yuan in 2019 and 300 million yuan in 2021 in China, which demonstrates its confidence in the Chinese market.
Roche's announcement of investment of this year comes ahead of the fifth China International Import Expo (CIIE), which is scheduled to be held from November 5 to 10 in the National Exhibition and Convention Center in Shanghai. Roche has participated in the previous four sessions of CIIE.
At this yea's CIIE, Roche, the world-leading maker of cancer drugs, will display nearly 30 heavyweight products on its 1,000 square meter-booth, including 10 global innovative products to be launched in China that cover haematology, breast cancer, ophthalmology, neuroscience and other areas.
Roche hopes to take advantage of CIIE to strengthen exchanges and cooperation with governments and partners, as well as gather resources to contribute to the development of China's healthcare industry, according to Bian Xin, CEO of Roche Pharmaceutical China. (Edited by Su Dan with Xinhua Silk Road, sudan@xinhua.org)
A single purchase
